Search


Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema
President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program. Coverage brought to you by
3 hours ago


Intellia's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy
Laura Sepp-Lorenzino shares details of this news and offers her opinion of the significance of it, and provides an overview of Intellia's...
Jun 26, 2024


The future of gene editing with Intellia’s CEO
Intellia Therapeutics CEO John Leonard on where he sees gene editing fitting into the practice of medicine.
Jun 23, 2023






.png)
